CBAK Energy Technology, Inc. Announces Significant Orders from Anker Innovations, totaling around USD 30 Million to 35 Million

CBAK Energy Technology, Inc. Announces Significant Orders from Anker Innovations, totaling around USD 30 Million to 35 Million

DALIAN, China, Dec. 27, 2024 /PRNewswire/ -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy" or the "Company"), a leading manufacturer of lithium-ion and sodium-ion batteries and electric energy solutions in China, today announced that...

UP YOUR SMART HOME GAME IN 2025 WITH ARLO

UP YOUR SMART HOME GAME IN 2025 WITH ARLO

SINGAPORE, Dec. 27, 2024 /PRNewswire/ -- Start off 2025 with security and peace of mind by equipping your house with Arlo's industry-leading smart home security solutions. From the best-in-class Arlo Ultra 2 4K Security Camera to the ever-popular...

Designs For Health Inc. Held Liable For Infringement of Kaneka's Ubiquinol Patent

Designs For Health Inc. Held Liable For Infringement of Kaneka's Ubiquinol Patent

TOKYO, Dec. 25, 2024 /PRNewswire/ -- Kaneka has successfully defended its patent for stabilizing Ubiquinol. On December 20, 2024, Kaneka Corporation won its lawsuit against Designs for Health, Inc. and American River Nutrition, LLC for infringement...

Health In Tech Announces Closing of Initial Public Offering

Health In Tech Announces Closing of Initial Public Offering

STUART, Fla., Dec. 25, 2024 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, today announced the closing of its initial public offering of 2,300,000 shares of its Class A common stock at a public...

Designing for the future: SM's vision through an architect's lens

Designing for the future: SM's vision through an architect's lens

PASAY CITY, Philippines, Dec. 23, 2024 /PRNewswire/ -- The SM Group, through its integrated property developer arm, SM Prime Holdings, Inc., is setting a benchmark in sustainable and disaster-resilient design. Embracing innovation, the company...

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial TEWKSBURY, Mass., Dec. 21, 2024 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it has...

Health In Tech, Inc. Announces Pricing of Initial Public Offering

Health In Tech, Inc. Announces Pricing of Initial Public Offering

STUART, Fla., Dec. 21, 2024 /PRNewswire/ -- Health In Tech, Inc., an Insurtech platform company backed by third-party AI technology, today announced the pricing of its initial public offering of 2,300,000 shares of its Class A common stock, at a...

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

Call for Entries Issued for 12th Annual Asia-Pacific Stevie® Awards

Call for Entries Issued for 12th Annual Asia-Pacific Stevie® Awards

New Awards Categories for Innovation of Individual Professionals FAIRFAX, Va., Dec. 20, 2024 /PRNewswire/ -- The Stevie® Awards are now accepting nominations for the 2025 (12th annual) Asia-Pacific Stevie® Awards, the only business awards program to...

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive $6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation. Patients...

  • 1
  • ...
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • ...
  • 29
  • menu
    menu